AFT PHARMACEUTICALS LIMITED — Director's Dealing 2020

Apr 23, 2020

==> picture [112 x 28] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited;and
Name of listed issuer:		AFT Pharmaceuticals Limited(AFT)
Date this disclosure made:		24-Apr-20
Date of last disclosure:		19-Jun-17
Director or senior managergivingdisclosure
Full name(s):		Malcolm Tubby
Name of listed issuer:		AFT Pharmaceuticals Limited(AFT)
Name of related bodycorporate(if applicable):		Not applicable
Position held in listed issuer:		Chief Financial Officer
Summary of acquisition or disposal of relevant interest(excluding specified derivatives)
Class of affected quoted financial products:		1. Unlisted options to acquire Fully-Paid Ordinary Shares in AFT (Ordinary Shares) 2. OrdinaryShares in AFT
Nature of the affected relevant interest(s):		Registered holder and beneficial interest
**For that relevant interest- **
Number held in class before acquisition or disposal:		1. 15,000 unlisted options 2. 100 OrdinaryShares
Number held in class after acquisition or disposal:		1. 0 unlisted options 2. 15,100 ordinaryshares
Current registered holder(s):		Malcolm Tubby
Registered holder(s)once transfers are registered:		Malcolm Tubby
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:		1
Details of transactions requiring disclosure-
Date of transaction:		23-Apr-20
Nature of transaction:		Exercise of 15,000 unlisted options and issue of 15,000 OrdinarySharespursuant to AFT Share Option Plan
Name of anyotherpartyorparties to the transaction(if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:		Exerciseprice of NZ$2.80per share / $42,000.00
Number of financialproducts to which the transaction related:		15,000
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		Not applicable
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closedperiod:		Not applicable
Date of theprior written clearance(if any):		Not applicable
Summary of other relevant interests after acquisition or disposal:
Class ofquoted financialproducts:		OrdinaryShares
Nature of relevant interest:		1. Joint registered holder and beneficial owner as trustee of the Jembag Trust 2. Power to control the exercise of the right to vote or dispose of financialproduct
_For that relevant interest,- _
Number held in class:		1. 75,218 2. 3,574
Current registered holder(s):		1. Barbara Tubby, Colin Tubby & Malcolm Tubby as trustees of the Jembag Trust 2. Barbara Tubby, Alison Tubby, Juliette Tubby, Emily Tubby,George Tubby
For a derivative relevant interest,-
Type of derivative:		Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):		Not applicable
A statement as to whether the derivative is cash settled orphysicallysettled:		Not applicable
Maturitydate of the derivative(if any):		Not applicable
Expirydate of the derivative(if any):		Not applicable
Theprice's specified terms(if any):		Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		Not applicable
_For that derivative relevant interest,- _
Parties to the derivative:		Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		Not applicable

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

==> picture [62 x 70] intentionally omitted <==

Signature of director or officer: Date of signature:

==> picture [532 x 46] intentionally omitted <==

24-Apr-20

==> picture [54 x 119] intentionally omitted <==